Investor Centre

Clinical stage drug developer Syntara Limited today announced that the Australian Securities and Investment Commission has issued a Certificate of Registration on Change of Name from Pharmaxis Ltd to Syntara Limited.  This follows approval at last week’s 2023 annual general meeting where the resolution to change the name was supported by 98% of voting shareholders.

The change in the Company’s ASX code from PXS to SNT is currently being processed by the ASX, with trading under the new code expected to commence by Friday 8 December 2023.